Xia

The impact of regulatory changes on rating behaviour

Retrieved on: 
화요일, 4월 2, 2024
Długosz, Disagreement, Pi bond, Direct lending, Key, Research Papers in Economics, Finance Secretary (India), University of Oxford, STS, Journal of Economic Perspectives, International, American Economic Review, Life, Columbia Business School, British Academy of Management, Risk assessment, ABS, Rating, EBA, Development, Reputational damage, OBS, CRA, Bond credit rating, Cras, Journal of Monetary Economics, CDO, Becker, Paper, 2007–2008 financial crisis, Raja, University, Environment, Journal of Financial Economics, Perception, H3, Website, Securitization, Working paper, Market, Collection, Total, European Banking Authority, Quarterly Journal of Economics, BBB, Whetten, Column, ESMA, European Journal, Issuer, Asset quality, Information revolution, Federal Reserve Bank, OLS, Statistics, PDF, Private, ECB, Surety, Weighted-average life, CCC, European Commission, Social science, Journal of Financial Stability, JEL, Real, Bias, Journal, Research, Classification, Certification, Commission, Credit, The Journal of Finance, Literature, Karel Škréta, European Central Bank, AA, Finance Research Letters, Origination (telephony), Monetary economics, Section 5, Xia, Kraft Foods, Government, AAA, Mukherjee, Finance, Deku, DOI, White, Risk, IOSCO, MBS, OECD, Wang, Section 4, University Challenge 2013–14, Section 3, Ashcraft, Financial management, Accounting, Financial economics, Fannie Mae, Conference, Pressure, Central bank, Griffin, University of Michigan, Systematic review, EPRS, Freddie Mac, Loan, BCBS, Palgrave Macmillan, R2, Microeconomics, Quarterly Journal, Financial statement analysis, The Japanese Economic Review, Christian Social Union (UK), Green, University of Huddersfield, PSM, Management, Security (finance), Security, Civil service commission, Private placement, American Economic Journal, GFC, Reproduction, IMF, Small business, Trustee, Data

Abstract

Key Points: 
    • Abstract
      We examine rating behaviour after the introduction of new regulations regarding Credit Rating
      Agencies (CRAs) in the European securitisation market.
    • There is empirical evidence of rating catering in the securitisation market in the pre-GFC period (He et al.,
      2012; Efing and Hau, 2015).
    • Competition among
      CRAs could diminish ratings quality (Golan, Parlour, and Rajan, 2011) and promotes rating shopping by
      issuers resulting in rating inflation (Bolton et al., 2012).
    • This paper investigates the impact of the post-GFC regulatory changes in the European
      securitisation market.
    • In 2011, in addition to the creation of
      European Securities and Markets Authority (ESMA), a regulatory and supervisory body for CRAs was
      introduced.
    • We examine how rating behaviours have changed in the European securitisation market after the
      introduction of these new regulations.
    • We utilise the existence of multiple ratings and rating agreements between
      CRAs to identify the existence of rating shopping and rating catering, respectively (Griffin et al., 2013; He
      et al., 2012; 2016).
    • We find that the regulatory changes have been effective in tackling conflicts of interest between issuers
      and CRAs in the structured finance market.
    • Rating catering, which is a direct consequence of issuer and
      CRA collusion, seems to have disappeared after the introduction of these regulations.
    • There is empirical evidence of rating catering in the securitisation market in
      the pre-GFC period (He et al., 2012; Efing and Hau, 2015).
    • Competition among CRAs could diminish ratings quality (Golan, Parlour,
      and Rajan, 2011) and promotes rating shopping by issuers resulting in rating inflation (Bolton et
      al., 2012).
    • This paper investigates the impact of the post-GFC regulatory changes in the European
      securitisation market.
    • In 2011, in addition
      to the creation of European Securities and Markets Authority (ESMA), a regulatory and
      supervisory body for CRAs was introduced.
    • We find that the regulatory changes have been effective in tackling conflicts of interest
      between issuers and CRAs in the structured finance market.
    • Rating catering, which is a direct
      consequence of issuer and CRA collusion, seems to have disappeared after the introduction of
      these regulations.
    • Investors who previously demanded higher spreads for rating agreements for a
      multiple rated tranche, did not consider the effect of rating harmony as a risk in the post-GFC
      period.
    • Regarding rating shopping, we find that the effectiveness of the changes has been limited,
      potentially for two reasons.
    • Additionally, we also find that rating over-reliance might still be an issue, especially
      Rating catering is a broad term and it can involve rating shopping.
    • They re-examine the rating shopping and rating
      catering phenomena in the US market by looking at the post-crisis period between 2009 and 2013.
    • Using 622 CDO tranches, they also observe the existence of rating shopping and the diminishing
      of the rating catering.
    • Firstly, our main focus is the EU?s CRA Regulation and its effectiveness in reducing
      rating inflation and rating over-reliance.
    • To the best of our knowledge, this paper is the first to
      examine the effectiveness of the EU?s CRA regulatory changes on the investors? perception of
      rating inflation in the European ABS market.
    • Hence, the coverage and quality of our dataset constitutes significant addition
      to the literature and allows us to test the rating shopping and rating catering more authoritatively.
    • The following section reviews the literature
      on securitisation concerning CRAs and conflicts of interest, and outlines the regulatory changes
      introduced in the post-GFC period.
    • Firstly, ratings became ever more important as the Securities and
      Exchange Commission (SEC) 5 began heavily relying on CRA assessments for regulatory purposes
      (i.e.
    • the investment mandates that highlight rating agencies as the main benchmark for investment
      eligibility) (SEC, 2008; Kisgen and Strahan, 2010; Bolton et al., 2012).
    • issuers) as one of the main explanations for the rating inflation (He et al., 2011; 2012; Bolton
      et al., 2012; Efing and Hau, 2015).
    • Bolton et al., (2012) demonstrate that competition
      promotes rating shopping by issuers, leading to rating inflation.
    • The last phase, CRA III, was implemented in mid-2013 and involves an additional
      set of measures on reducing transparency and rating over-reliance.
    • As mentioned above, rating inflation can be caused by rating shopping
      In order to be eligible to use the STS classification, main parties (i.e.
    • The higher the difference in the number of ratings for a
      given ABS tranche, the greater the risk of rating shopping.
    • Alternatively, the impact of the new
      regulations could be limited when it comes to reducing rating shopping.
    • This is because, firstly,
      the conflict of interest between securitisation parties is not necessarily the sole cause for the
      occurrence of rating shopping.
    • L is a set of variables (Multiple ratings, CRA reported, Rating agreement) that
      we utilise interchangeably to capture the rating shopping and rating catering behaviour.
    • Hence, issuers are incentivised to report the highest possible rating and
      ensure each additional rating matches the desired level.
    • All in all, our results suggest that
      the new stricter regulatory measures have been effective in tackling conflicts of interest and
      reducing rating inflation caused by rating catering.
    • Self-selection might be a concern in analysing the impact of the
      new measures and investors? response with regard to the rating inflation.
    • This
      result is in line with the earlier findings suggesting that regulatory changes have reduced investors?
      suspicion of rating inflation and increased trust of CRAs.
    • Conclusion
      Several regulatory changes were introduced in Europe following the GFC aimed at tackling
      conflicts of interest between issuers and CRAs in the ABS market.
    • Utilising a sample of 12,469
      ABS issued between 1998 and 2018 in the European market, this paper examined whether these
      changes have had any impact on rating inflations caused by rating shopping and rating catering
      phenomena.
    • We find that the
      effectiveness of the changes has been more limited on rating shopping potentially for two reasons.
    • Tranche Credit Rating is the rating reported for a tranche at launch.

GC Biopharma Announces US FDA Approval for ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)

Retrieved on: 
월요일, 12월 18, 2023

The ALYGLO pivotal phase 3 clinical study followed FDA guidance for the treatment of patients with PI.

Key Points: 
  • The ALYGLO pivotal phase 3 clinical study followed FDA guidance for the treatment of patients with PI.
  • ­­The results of the phase 3 trial by GC Biopharma are published in Frontiers in Immunology (2021).
  • Dr. Eun-chul Huh, President and CEO of GC Biopharma, said, "The approval of ALYGLO by the US FDA is a significant milestone for GC Biopharma and patients with primary immunodeficiency disease.
  • For any medical or scientific questions regarding ALYGLO, call the GC Biopharma USA medical department at 1-833-426-6426, or email [email protected] .

Global Times: Over 12,000 artifacts excavated from Sanxingdui Ruins site as latest achievements of civilization-tracing project revealed

Retrieved on: 
월요일, 12월 11, 2023

Among the noteworthy breakthroughs is the preliminary understanding of the distribution and internal structure of the sacrificial area at the world-renowned Sanxingdui Ruins site.

Key Points: 
  • Among the noteworthy breakthroughs is the preliminary understanding of the distribution and internal structure of the sacrificial area at the world-renowned Sanxingdui Ruins site.
  • The project suggests that approximately 5,800 years ago, distinct social differentiation emerged across various regions of China, marking the accelerated phase of Chinese civilization.
  • Li noted that compared to the fourth phase of the project, the current archaeological work has deepened our understanding of this era.
  • Looking ahead, the NCHA plans to further advance and deepen the national project, combining archaeology, literature research, and scientific methods.

Global Times: President Xi's visit to Xinjiang region encourages spirit of development, unity and innovation

Retrieved on: 
목요일, 9월 14, 2023

We were deeply touched by the president's love and care for Xinjiang region, and for his people," Kelibinur Yasen told the Global Times.

Key Points: 
  • We were deeply touched by the president's love and care for Xinjiang region, and for his people," Kelibinur Yasen told the Global Times.
  • Kelibinur Yasen is a villager from the remote Xinchengximen Village in Turpan, Northwest China's Xinjiang Uygur Autonomous Region.
  • Global Times reporters went on a fact-finding mission to Xinchengximen Village on Friday to find out the answer.
  • As a college student at Xinjiang University, she was offered other intern opportunities outside of Xinjiang region but she turned them down.

Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation

Retrieved on: 
목요일, 5월 25, 2023

The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients.

Key Points: 
  • The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients.
  • The Librexia program is unrivaled as the most comprehensive FXIa clinical development program to date and will provide extensive data from nearly 50,000 patients.
  • Fast Track Designation encourages close communication between the FDA and sponsor to improve the efficiency of product development, with the aim of getting new therapeutics to patients faster.
  • “This Fast Track Designation underscores the unmet need that exists in the treatment of thromboembolic conditions,” said Puneet Mohan, MBBS, MD, PhD, vice president, Global Program Lead, Milvexian, Bristol Myers Squibb.

SAI.TECH Announces Appointment of AI and Data Center Technical consultant

Retrieved on: 
금요일, 4월 21, 2023

Before Intel, Mr Xia was staff engineer at Lenovo Group Ltd responsible for thermal design and implementation of HPC products.

Key Points: 
  • Before Intel, Mr Xia was staff engineer at Lenovo Group Ltd responsible for thermal design and implementation of HPC products.
  • Adrian Xia will be responsible for providing professional consultation for SAI.TECH, helping with the strategic development of the software and hardware of the HPC and AI industry.
  • Adrian Xia will be guiding the design of the whole business model and technical path to achieve sustainable energy for AI computing industry.
  • "We are proud to have Adrian Xia joined us as AI and Data Center Technical consultant to help us with improving our HPC business line while promoting our theory and mission to the public."

The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor

Retrieved on: 
목요일, 3월 2, 2023

Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen) today announced the launch of the Phase 3 Librexia program studying milvexian, an investigational oral factor XIa (FXIa) inhibitor (antithrombotic).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen) today announced the launch of the Phase 3 Librexia program studying milvexian, an investigational oral factor XIa (FXIa) inhibitor (antithrombotic).
  • The Librexia program is unrivaled as the most comprehensive FXIa development program to date and will provide important data from nearly 50,000 patients across three indication-seeking studies: Librexia STROKE, Librexia ACS and Librexia AF.
  • Enrollment has begun for the Librexia STROKE trial, which is evaluating milvexian in addition to standard of care antiplatelet therapy for stroke prevention in patients after an acute ischemic stroke or high-risk transient ischemic attack.
  • More information on the Librexia STROKE trial can be found on http://www.clinicaltrials.gov (NCT05702034).

Bayer Announces First Patients Enrolled in Global Phase III Studies for Investigational Oral FXIa Inhibitor Asundexian

Retrieved on: 
수요일, 2월 8, 2023

“Additional research into the combination of FXI inhibition and antiplatelet agents is needed to explore potential treatment options for the future.”

Key Points: 
  • “Additional research into the combination of FXI inhibition and antiplatelet agents is needed to explore potential treatment options for the future.”
    “Through our OCEANIC clinical trial program, Bayer leverages decades of cardiovascular expertise to investigate a potential new class of antithrombotics and explore the potential of asundexian as an additional antithrombotic treatment option across multiple patient populations,” 1-2 said Maria Borentain, M.D., Vice President and Head of Thrombosis and Vascular Disease Clinical Development, Bayer.
  • Effect of factor XIa inhibition with asundexian on recurrent ischemic stroke according to baseline patterns of infarction on brain MRI: PACIFIC-Stroke.6
    Khatri P, Shoamanesh A, Mundl H, et al.
  • Effects of the oral factor XIa inhibitor asundexian on intracranial bleeding among patients with acute non-cardioembolic ischemic stroke: PACIFIC-Stroke randomized trial.
  • 7

Hong Kong Heritage Discovery Centre holds "Light of Jinsha - The Ancient Shu Civilisation" exhibition

Retrieved on: 
금요일, 12월 30, 2022

HONG KONG, Dec 30, 2022 - (ACN Newswire) - An exhibition entitled "Light of Jinsha - The Ancient Shu Civilisation" is now open at the Hong Kong Heritage Discover Centre.

Key Points: 
  • HONG KONG, Dec 30, 2022 - (ACN Newswire) - An exhibition entitled "Light of Jinsha - The Ancient Shu Civilisation" is now open at the Hong Kong Heritage Discover Centre.
  • The "Light of Jinsha - The Ancient Shu Civilisation" exhibition opens from December 30 to March 29, 2023 at the Hong Kong Heritage Discovery Centre.
  • The Jinsha site, a major archaeological discovery in 2001, is another political, economic and cultural centre established by the ancient Shu people in Chengdu Plain after the Sanxingdui civilisation.
  • The exhibition is held at the Hong Kong Heritage Discovery Centre, Kowloon Park, Haiphong Road, Tsim Sha Tsui until March 29, 2023.

Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian

Retrieved on: 
일요일, 8월 28, 2022

The underlying science of FXIa and Phase II PACIFIC data provide a foundation on which to advance asundexian forward into the OCEANIC Phase III program, one of the largest Phase III endeavors Bayer has undertaken.1-2

Key Points: 
  • The underlying science of FXIa and Phase II PACIFIC data provide a foundation on which to advance asundexian forward into the OCEANIC Phase III program, one of the largest Phase III endeavors Bayer has undertaken.1-2
    The PACIFIC clinical trials form part of the broadest Phase IIb FXIa program in the world, involving more than 4,000 patients to date.3-5 The program is part of Bayers commitment to address unmet needs in a growing range of underserved cardiovascular patient communities.
  • Asundexian is a once-daily, oral investigational agent and has not been approved by any health authority for use in any country, for any indication.
  • Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack (PACIFIC-AMI).
  • Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.